SKI 606
380843-75-4
530.5
C26H29Cl2N5O3
DMF, DMSO, Ethanol, PBS (pH 7.2)
-20°C
Bosutinib is a novel tyrosine kinase inhibitor. Bosutinib can overcome not only Bcr-Abl-dependent mechanisms of resistance, but also those that are Bcr-Abl-independent. It is used to treat patients with chronic myelogenous leukemia (CML) who demonstrate resistance to Imatinib or develop resistance during treatment.
0.1 lbs
Research or further manufacturing use only, not for food or drug use.
